$20.8 Million is the total value of INTERWEST VENTURE MANAGEMENT CO's 5 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VERO | Exit | VENUS CONCEPT INC | $0 | – | -658,657 | -100.0% | -0.89% | – |
| AGTC | Exit | APPLIED GENETIC TECHNOL CORP | $0 | – | -1,404,515 | -100.0% | -1.17% | – |
| EIGR | Exit | EIGER BIOPHARMACEUTICALS INC | $0 | – | -560,990 | -100.0% | -13.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-01-31
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLAUKOS CORP | 28 | Q3 2023 | 33.0% |
| EIGER BIOPHARMACEUTICALS INC | 24 | Q3 2022 | 17.7% |
| APPLIED GENETIC TECHNOL CORP | 24 | Q3 2022 | 6.7% |
| XENON PHARMACEUTICALS INC | 20 | Q3 2021 | 0.6% |
| CIDARA THERAPEUTICS INC | 19 | Q2 2021 | 4.5% |
| THE REALREAL | 18 | Q3 2023 | 62.6% |
| KALVISTA PHARMACEUTICALS INC | 17 | Q4 2020 | 10.8% |
| DARE BIOSCIENCE INC | 16 | Q3 2023 | 0.3% |
| MACROGENICS INC | 14 | Q1 2020 | 19.2% |
| PMV PHARMACEUTICALS INC | 13 | Q3 2023 | 67.5% |
View INTERWEST VENTURE MANAGEMENT CO's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 144 | 2024-02-27 |
| 13F-HR | 2023-10-20 |
| 13F-HR | 2023-07-21 |
| 13F-HR | 2023-04-27 |
| 13F-HR | 2023-01-31 |
| 13F-HR | 2022-10-25 |
| 13F-HR | 2022-08-02 |
| 13F-HR | 2022-04-13 |
| 13F-HR | 2022-01-25 |
| 13F-HR | 2021-10-19 |
View INTERWEST VENTURE MANAGEMENT CO's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.